Addressing the Global Disparities in Access to Treatment in Spinal Muscular Atrophy. [PDF]
Koutsioumpa C +3 more
europepmc +1 more source
Clinical evaluation of ThecaFlex DRx, a novel implantable catheter-port for intrathecal nusinersen delivery in spinal muscular atrophy: Initial results from the PIERRE-IDE study. [PDF]
Mesina-Estarrón I +10 more
europepmc +1 more source
Motor function and safety of nusinersen for spinal muscular atrophy: a systematic review and meta-analysis among Chinese patients. [PDF]
He G +5 more
europepmc +1 more source
Comparative Characterization of a Proposed Generic Nusinersen: Identity of the Oligonucleotide Structure and Equivalence in SMN2 Splicing Activity. [PDF]
Taran S +4 more
europepmc +1 more source
Therapeutic oligonucleotides as genetic medicines: The current state and future perspective. [PDF]
Godinho BMDC +2 more
europepmc +1 more source
Treatment of risdiplam after nusinersen continuously improves upper limb motor function in spinal muscular atrophy patients: a multicenter experience. [PDF]
Cheng X +6 more
europepmc +1 more source
Glymphatic Dysfunction in Children With Type 2 and 3 Spinal Muscular Atrophy. [PDF]
Lan S +10 more
europepmc +1 more source
MyomiR Networks in Spinal Muscular Atrophy: Associations With Clinical Severity and Treatment Response. [PDF]
Barbo M +4 more
europepmc +1 more source
Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study. [PDF]
Chovi-Trull M +8 more
europepmc +1 more source

